
    
      This study will consist of a Safety Run-in Cohort 1 (magrolimab + docetaxel combination).
      After completion of the Safety Run-in Cohort 1, Phase 2 Cohort 1 will occur as follows:

        -  Phase 2 Cohort 1: a cohort of participants with solid tumors (metastatic non-small cell
           lung cancer (mNSCLC) (Phase 2 Cohort 1a), metastatic urothelial cancer (mUC) (Phase 2
           Cohort 1b), and metastatic small cell lung cancer (mSCLC) (Phase 2 Cohort 1c).
    
  